Fate Therapeutics, UC San Diego Launch CAR NK Cancer Immunotherapy Collaboration – Genetic Engineering & Biotechnology News
|
Fate Therapeutics, UC San Diego Launch CAR NK Cancer Immunotherapy Collaboration
Genetic Engineering & Biotechnology News Fate Therapeutics said today it will develop off-the-shelf, chimeric antigen receptor (CAR)-targeted natural killer (NK) cell cancer immunotherapies through a research collaboration with the University of California, San Diego. The collaboration—whose … Fate Therapeutics and University of California San Diego Launch Research Collaboration to Develop iPSC-Derived … |
